Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
treatment-resistant tumors
Biotech
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Genentech is paying $45 million upfront for rights to ADCs designed for the growing pool of patients who progress after treatment with the modality.
Nick Paul Taylor
Aug 28, 2026 4:30am
Kura posts data on drug designed to unleash KRAS inhibitors
May 26, 2026 10:09am
Fighting drug-resistant cancer by blocking an escape route
Jan 5, 2022 8:35am
Treating resistant prostate cancer via tumor-suppressing RNA
Nov 5, 2021 10:00am
Tyra banks $173M to bring cancer resistance programs into clinic
Sep 15, 2021 10:20am
Tyra Biosciences wants to bank $100M for an IPO
Aug 23, 2021 7:05am
